Which one of LDL-C /HDL-C ratio and non-HDL-C can better predict the severity of coronary artery disease in STEMI patients

Po Gao*, Xiang Wen, Qiaoyun Ou and Jing Zhang

Abstract

Background: The increase of low-density lipoprotein cholesterol (LDL-C) is widely accepted as an important factor in the occurrence of atherosclerosis. In recent years, the guidelines have recommended non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for lipid-lowering therapy. But even as research on the relationship between LDL-C/HDL-C and atherosclerosis increases, it is still undetermined which index is most closely related to the severity of acute ST-segment elevation myocardial infarction (STEMI).

Methods: 901 patients who received coronary angiography due to chest pain were selected. Among them, 772 patients with STEMI represented the test group, and 129 patients with basically normal coronary angiography represented the control group. Researchers measured fasting blood lipids and other indicators after admission, and determined the severity of coronary artery disease using the Gensini score.

Results: LDL-C/HDL-C and non-HDL-C indexes were statistically different between the two patient groups. In the test group, total cholesterol (TC), triglycerides (TG), LDL-C, high density lipoprotein cholesterol (HDL-C), non-HDL-C, arteriosclerosis index (AI), and LDL-C/HDL-C all correlated with the patients’ Gensini score. After applying the stepwise method of multiple linear regression analysis ($R^2 = 0.423, \beta = 0.518, p < 0.05$), LDL-C/HDL-C had the most correlation with the patient’s Gensini score. ROC curve analysis suggested that LDL-C/HDL-C can predict whether patients with chest pain are STEMI ($AUC = 0.880, 95\% CI: 0.847–0.912, p < 0.05$). When cutoff value is 2.15, sensitivity is 0.845, and specificity is 0.202, LDL-C/HDL-C is an effective indicator for predicting whether patients with chest pain have STEMI.

Conclusion: Compared to ratios of non-HDL-C and LDL-C, the LDL-C/HDL-C ratio in patients with STEMI is more correlated with the severity of coronary artery disease. It can better evaluate the severity of coronary artery disease and better predict whether patients with chest pain are STEMI.

Keywords: STEMI, LDL-C/HDL-C, Non-HDL-C, Gensini score

Introduction

The formation of atherosclerosis is a slow and complex process. Its pathogenesis, recognized as "Injury Response Theory," [1] can be generally divided into three processes: (1) physical or chemical factors stimulate the arterial intima and blood lipid adheres to the blood vessel wall due to injury; (2) blood lipids are deposited in the injured arterial intima, stimulating further injury of the arterial intima and resulting in further deposition; (3) fat deposition stimulates the proliferation of smooth muscle cells and fibroblasts in the inner wall of the artery and the proliferation continues to develop into fibrous plaques. Excessive lipid deposition can also aggravate...
the inflammatory reaction by promoting the secretion of inflammatory mediators and aggravating atherosclerosis. STEMI is caused by coronary artery occlusion or thrombosis due to injury, or rupture of coronary artery lipid plaque. Hyperlipidemia management should hold a central pathogenic role among risk factors for coronary heart disease, and control of blood lipids should be the key treatment goal.

The main indicators included in the blood lipid profile are TG, TC, HDL-C, LDL-C, very low-density lipoprotein cholesterol (VLDL-C), etc. Lipid metabolism disorder has always been a contentious issue in the field of coronary heart disease (CHD) research. An increase in both TC and LDL-C is widely accepted as an important factor in the occurrence of atherosclerosis [2]. Later studies have confirmed that TG also causes atherosclerosis, while HDL-C has an anti-atherosclerotic effect [3]. Recently, studies have shown that indicators such as AI, non-HDL-C, and LDL-C/HDL-C are closely related to CHD and other clinical diseases [4]. In particular, there are many studies on non-HDL-C and LDL-C/HDL-C.

As of now, the blood lipid guidelines in the United States and Europe still regard LDL-C as the primary goal of blood lipid control [5], while non-HDL-C and LDL-C/HDL-C are regarded as secondary goals. Although many studies have detailed the above two indicators, the indicators still present the outer range of coronary heart disease, and no results clearly show what boundary value of the two indicators would require intervention. The most serious type of coronary heart disease, STEMI has a high mortality rate and poor prognosis. This study explores the above two indicators’ evaluative effect on the severity of coronary artery disease in STEMI patients, both weighing which of the two indicators evaluates severity more effectively, and identifying the boundary value that requires intervention.

Methods
The records of 901 patients who received coronary angiography due to chest pain in the hospital from September 2014 to September 2020 were retrospectively analyzed. Among them, 772 were STEMI patients, and 129 patients had basically normal coronary angiography. The 2018 "Global Definition of the Fourth Myocardial Infarction" was used as diagnostic criteria; previous history of myocardial infarction, malignant tumors, severe infections, liver and kidney insufficiency, and past history of lipid-lowering drugs were excluded. Patient gender, age, history of diabetes, history of hypertension, smoking habits, height, and weight were recorded. The selected patients underwent a blood test, electrocardiogram, and coronary angiography at the time of admission and a blood lipid test the next morning (including TC, TG, LDL-C, HDL-C, VLDL-C). Gensini score, a classic coronary artery lesion severity scoring system, can comprehensively reflect the degree and extent of coronary artery stenosis. The Gensini score was used to evaluate the severity of coronary lesions. The calculation of the score is as follows: First, the evaluator scores the stenosis according to the degree of coronary artery stenosis: left main coronary artery (LM) lesion × 5; left anterior descending branch (LAD) lesion, distal segment × 1; middle segment × 1.5, proximal segment × 2.5; diagonal branch lesion, first diagonal branch (D1) × 1, second diagonal branch (D2) × 0.5; left circumflex branch (LCX) lesion, distal segment × 1, proximal segment × 2.5; obtuse marginal branch × 1, posterior descending branches × 1; posterior branches of left ventricular × 0.5. The lesions of right coronary artery (RCA) included proximal, middle, distal and posterior descending branches, each segment × 1. Thirdly, the evaluator must multiply the coronary artery stenosis score by its corresponding coefficient, giving the lesion score. The sum of the lesion scores is the Gensini score. Two physicians recorded detailed statistics on the location of coronary artery lesions and the degree of stenosis in each patient. The degree of coronary artery lesions was scored using the Gensini score. In the case of disagreement, a third physician formed a joint discussion to make a decision. The non-HDL-C calculation method is TC minus HDL-C, and the AI calculation method is TC minus HDL-C then divided by HDL-C.

Statistical analysis
Non-normal distribution measurement data are represented by M (Q1, Q3). An independent sample t test or a Mann–Whitney U test is used for comparison of measurement data between two groups. A chi-squares test is used for comparison of count data. The correlation between variables is analyzed by either Pearson linear correlation analysis or logistic regression analysis, and the results are expressed in terms of correlation coefficient r or ratio OR and 95% confidence interval 95% CI. Multivariate correlation is analyzed by multiple linear regression with variable selection. The introduction level is entered as 0.05 and the elimination level is 0.10. The result is expressed by the determination coefficient R² and the standardized regression coefficient β. All the above test results are statistically significant, with a bilateral p < 0.05 as the difference. All data were analyzed and processed by SPSS 22.0.
Results
Baseline clinical characteristics
A total of 901 patients were included in the study, 670 males (74.4%) and 231 females (25.6%). According to the results of their coronary angiography, patients were divided into a test group (772 STEMI patients) and a control group (129 normal patients). Table one summarizes the baseline characteristics and laboratory data of the patients (Table 1).

Indexes such as body mass index (BMI), diabetes history, history of hypertension, smoking habits, absolute neutrophil count (ANC), total lymphocyte count (TLC), and TC, TG, HDL-C, LDL-C, VLDL-C, non-HDL-C, AI, and LDL-C/HDL-C were significantly different in the two groups of patients.

Correlation between related indexes in blood lipids and Gensini score
Correlation analysis of TC, TG, HDL-C, LDL-C, VLDL-C, non-HDL-C, AI, and LDL-C/HDL-C and Gensini scores of all test groups of patients found that TC, TG, HDL-C, LDL-C, non-HDL-C, AI, and LDL-C/HDL-C are all correlated with Gensini score. Among them, TC, TG, LDL-C, non-HDL-C, AI, and LDL-C/HDL-C are positively correlated with Gensini score. HDL-C was negatively correlated with Gensini score (Table 2 and Fig. 1).

Multivariate correlation analysis of Gensini scores
In further analysis, the Gensini score was used as the dependent variable, and all the above correlation indicators, along with hypertension, diabetes, and smoking, were used as independent variables to perform multiple linear regression stepwise analysis. LDL-C/HDL-C, non-HDL-C, AI, TG, hypertension, diabetes, and smoking entered the analysis, LDL-C/HDL-C and non-HDL-C still had a positive correlation with Gensini score ($R^2 = 0.423$, $\beta = 0.518$, $\beta = 0.150$, $p < 0.05$). (Table 3).

The predictive effect of LDL-C, non-HDL-C, and LDL-C/HDL-C on STEMI patients
The control group was regarded as a low Gensini score group, while the test group was regarded as a high Gensini score group. LDL-C/HDL-C, non-HDL-C, and LDL-C were used as independent variables to calculate the ROC curve. The ROC curve of LDL-C/HDL-C was

| Variables                  | Test group (n = 772) | Control group (n = 129) | $\chi^2/z$ | p   |
|----------------------------|---------------------|-------------------------|------------|-----|
| age                       | 62.75 (53.00,72.00) | 59.37 (50.50,69.00)     | 1.347      | 0.178|
| Sex (%)                   | Male 586 (75.9%)    | Male 84 (65.1%)         | 6.750      | 0.009|
| Female 186 (24.1%)        |                     |                         |            |     |
| Hypertension (%)           | 442 (57.3%)         | 59 (45.7%)              | 6.441      | 0.040|
| Diabetes (%)               | 328 (42.5%)         | 36 (27.9%)              | 10.003     | 0.007|
| Smoker (%)                 | 442 (57.3%)         | 46 (35.7%)              | 20.762     | 0.000|
| BMI (kg/m²)               | 23.64 (22.00, 25.00)| 22.50 (20.00, 24.00)    | 4.508      | 0.000|
| ANC (X10⁹)                | 5.85 (4.5, 6.84)    | 3.91 (3.09, 4.43)       | 9.243      | 0.000|
| TLC (X10⁹)                | 1.91 (1.57, 2.29)   | 2.12 (1.53, 2.64)       | 7.570      | 0.000|
| RBC (X10⁹)                | 4.36 (3.94, 4.81)   | 4.38 (3.94, 4.76)       | 1.400      | 0.888|
| TC (mmol/L)               | 4.38 (3.70, 4.93)   | 3.67 (3.09, 4.35)       | 8.143      | 0.000|
| TG (mmol/L)               | 1.60 (1.04, 1.87)   | 1.38 (0.93, 1.66)       | 2.334      | 0.020|
| HDL-C (mmol/L)            | 0.91 (0.76, 1.01)   | 1.14 (0.94, 1.23)       | 7.770      | 0.000|
| LDL-C (mmol/L)            | 2.60 (2.03, 3.10)   | 1.83 (1.46, 2.30)       | 9.631      | 0.000|
| VLDL (mmol/L)             | 0.74 (0.49, 0.88)   | 0.59 (0.37, 0.73)       | 3.211      | 0.010|
| LDL-C/HDL-C               | 2.98 (2.27, 3.50)   | 1.69 (1.20, 2.11)       | 9.806      | 0.000|
| Non-HDL-C (mmol/L)        | 3.47 (2.80, 4.01)   | 2.53 (1.93, 3.10)       | 9.020      | 0.000|
| AI                        | 4.03 (3.00, 4.73)   | 2.15 (1.67, 3.08)       | 9.401      | 0.000|

Table 1 Baseline Clinical Characteristics

Table 2 Correlation between related indexes in blood lipids and Gensini score

| Variables       | r     | 95% CL    | p   |
|-----------------|-------|-----------|-----|
| TC (mmol/L)     | 0.422 | 9.145, 12.418 | 0.000|
| TG (mmol/L)     | 0.103 | 0.800, 1.287 | 0.004|
| HDL-C (mmol/L)  | -0.260| -30.400, -20.920 | 0.000|
| LDL-C (mmol/L)  | 0.527 | 14.440, 18.157 | 0.000|
| VLDL-C (mmol/L) | 0.006 | -3.492, 4.152 | 0.865|
| Non-HDL-C (mmol/L) | 0.490 | 11.019, 14.193 | 0.000|
| AI              | 0.528 | 7.524, 9.458 | 0.000|
| LDL-C/HDL-C     | 0.616 | 12.020, 14.413 | 0.000|


AUC: 0.880, 95% CI: 0.847–0.912, p < 0.05, with a cutoff value of 2.15, a sensitivity of 0.845, and a specificity of 0.202. The ROC curve of non-HDL-C was AUC: 0.782, 95% CI: 0.739–0.826, p < 0.05, with a cutoff value of 2.52, a sensitivity of 0.870, and a specificity of 0.426. The ROC curve of LDL-C was AUC: 0.787, 95% CI: 0.748–0.826, p < 0.05, with a cutoff value of 2.35, a sensitivity of 0.578, and a specificity of 0.829 (Fig. 2). Compared with non-HDL-C and LDL-C, LDL-C/HDL-C can better predict whether patients with chest pain are STEMI.

**Table 3**  Multivariate correlation analysis of Gensini scores

| Variables                  | SD   | β    | t    | p    |
|----------------------------|------|------|------|------|
| LDL-C/HDL-C                | 0.756| 0.518| 14.720| 0.000|
| Non-HDL-C (mmol/L)         | 0.918| 0.150| 4.198 | 0.000|
| TG (mmol/L)                | 0.695| 0.058| 2.076 | 0.038|
| Diabetes                   | 1.365| 0.115| 4.166 | 0.000|
| Hypertension               | 1.385| 0.100| 3.554 | 0.000|
| Smoking                    | 1.361| 0.068| 2.473 | 0.014|

LDL-C/HDL-C as an independent risk factor for STEMI

In order to further clarify the above three indicators as risk factors for STEMI, the team performed a binary logistic regression analysis. Taking the control group as the low Gensini score group and the test group as the high Gensini score group, with LDL-C/HDL-C, non-HDL-C, and LDL-C as independent variables and Gensini score as the dependent variable, binary logistic regression analysis shows that LDL-C/HDL-C is an independent risk factor for STEMI (OR=1.538, 95% CI: 1.117–2.119, p < 0.05), further validating LDL-C/HDL-C’s effectiveness as an index predictor of STEMI. (Table 4, Fig. 3).

**Discussion**

High serum concentration of LDL-C is an important risk factor for CHD. Previous studies have shown that oxidatively modified low-density lipoprotein cholesterol (ox-LDL-C) plays a key role in the pathogenesis of atherosclerosis [6]. ox-LDL-C has a low affinity for the scavenger receptors of macrophages. As it enters blood circulation, it stimulates the release of adhesion molecules and chemokines, which are then absorbed by macrophages through scavenger receptors, leading to the formation of foam cells. This reaction leads to development and progression of coronary atherosclerosis [7].

The role of HDL-C in CHD is relatively clear. Studies have shown that low levels of HDL-C increase the risk of CHD [8]. The incidence of coronary heart disease doubles...
in people with HDL-C levels lower than 40 mg/dL. Even with LDL-C under 70 mg/dL or TC under 200 mg/dL, patients with low HDL-C still have a significant risk of CHD [9]. Patients with low levels of LDL-C and HDL-C are still at high risk of atherosclerosis. At present, LDL-C is mainly used clinically to predict the risk of atherosclerotic cardiovascular disease. However, though clinical intervention can help patients’ LDL-C level reach the recommended 1.4 mmol/L, some will still develop atherosclerosis. Clinicians still seek better indicators to control the residual risk of ASCVD [5], so the ratios of AI, non-HDL-C, and LDL-C/HDL-C in the blood lipid profile have attracted attention. Changes in these ratios are proven indicators for evaluating CHD risk [10, 11].

Previous studies show that AI and low-density lipoprotein cholesterol (sd-LDL-C) have a significant negative correlation; moreover, sd-LDL-C is strongly related to coronary artery spasm, angina pectoris, and coronary artery stenosis [12]. Recently, an increasing number of analyses have shown that AI is related not only to atherosclerosis, but also to insulin resistance. In 2001, the United States National Cholesterol Education Program (NCEP) first evaluated non-HDL-C as a concept [13]. The latest 2019 European Society of Cardiology/European Society of Arteriosclerosis guidelines further adjusted the target values of LDL-C and non-HDL-C. For patients with extremely high cardiovascular risk, the recommended primary goal is LDL-C < 1.4 mmol/L (or LDL-C reduction > 50%), and the recommended secondary goal is non-HDL-C < 2.2 mmol/L [5].

There is a positive linear correlation between LDL-C/HDL-C ratio and changes in coronary plaque volume [14]. Vulnerable plaque is the main cause of CHD. Increased ratio of LDL-C/HDL-C is a predictor of coronary artery lipid-rich plaque and plaque vulnerability, conditions which can lead to an increased risk of sudden death [15, 16]. Coronary thrombosis is mainly caused by rupture of high-risk vulnerable plaques, which ultimately lead to acute myocardial infarction. The ratio of LDL-C/HDL-C can also inform lipid-lowering therapy; additionally, it is an evaluation index for prognosis of CHD patients [17]. Data from clinical trials [18] associates high LDL-C/HDL-C ratio with plaque progression in the coronary arteries. The reduction of the LDL-C/HDL-C ratio through drug intervention may be related to the reduction of coronary plaque [19].

Studies evaluating the above two indicators, though high in quantity, mainly examine the larger scope of coronary heart disease. This study, on the other hand, explores whether the above two indicators have an evaluative effect on the severity of coronary artery disease in STEMI patients, identifies which of the two can
better gauge the severity of coronary artery disease in STEMI patients, and determines the boundary value that requires intervention.

Hypertension, hyperglycemia, high LDL-C, and smoking are very clear risk factors for atherosclerosis. But even after controlling these risk factors, some patients still experience cardiovascular events. These remaining causes are residual risks for cardiovascular events. The levels of HDL-C and triglyceride in the blood lipid profile are important residual risks [20].

In our study, indexes such as BMI, diabetes history, history of hypertension, smoking habits, ANC, TLC, TC, TG, HDL-C, LDL-C, VLDL-C, non-HDL-C, AI, and LDL-C/ HDL-C were significantly different in the two groups of patients ($p<0.05$), demonstrating that the above indicators are high-risk factors for STEMI, a finding that is consistent with previous studies. The TC, TG, LDL-C, HDL-C, non-HDL-C, AI, and LDL-C/ HDL-C of STEMI patients correlated with the patient’s Gensini score.

Because smoking, hypertension, and diabetes greatly impact the progression of coronary heart disease, we used those three factors, along with the above seven indicators, as independent variables, and Gensini score as the dependent variable. Stepwise multiple linear regression analysis found that the two indicators of LDL-C/HDL-C and non-HDL-C had a positive correlation with the Gensini score ($R^2 = 0.423$, $\beta = 0.518$, $\beta = 0.150$, $p<0.05$), with LDL-C/HDL-C being the most relevant. Even after treating other risk factors like smoking, hypertension, and diabetes, LDL-C/ HDL-C and Gensini score still have significant correlation with severity of coronary artery disease in STEMI patients. Further analysis found that LDL-C/HDL-C can accurately predict whether patients with chest pain are STEMI (AUC: 0.880, 95% CI: 0.847–0.912; $p<0.05$). When the cut-off value is 2.15, the sensitivity is 0.845 and the specificity is 0.202. This is a high sensitivity. When the ratio of LDL-C/HDL-C is greater than 2.15, patients with chest pain are more likely to have STEMI.

**Conclusion**

We found that LDL-C/HDL-C works more effectively than non-HDL-C not only in evaluating the severity of coronary artery disease in STEMI patients, but also in predicting whether patients with chest pain are STEMI.

Current diagnosis and treatment guidelines recommend that patients’ serum LDL-C levels be used to assess the risk of ASCVD. However, as mentioned above, even patients with well-controlled LDL-C are at risk of ASCVD. LDL-C’s propensity for causing cardiovascular disease has earned it the nickname “bad cholesterol,” while HDL-C, which has a protective effect on the cardiovascular system, is often called “good cholesterol.” When the patient’s serum LDL-C and HDL-C levels are both low, the patient is at risk of cardiovascular disease. Using exclusively LDL-C to assess patients’ risk of cardiovascular disease has its limitations; non-HDL-C and LDL-C/ HDL-C combined can more comprehensively assess the risk of cardiovascular disease than LDL-C alone.

We found that LDL-C/HDL-C is more related to the severity of coronary artery disease in STEMI patients than LDL-C and non-HDL-C. The lower the serum LDL-C/HDL-C level, the lower the risk of STEMI. In clinical diagnosis and treatment, when using traditional LDL-C to assess the patient’s lipid control, we should also consider both LDL-C and HDL-C, thus reducing residual risks.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02760-0.

**Additional file 1.** Research data.

**Acknowledgements**

The authors of this study would like to thank all the organizations, individuals, and participants who supported the project.

**Author contributions**

PG and JZ were responsible for data analysis, paper writing, and important research parts. They also approved the final published version of the paper. XW and QO were responsible for data collection and sorting. All authors read and approved the final manuscript.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the An Hui Province Science Foundation of China. (No.20210407020058).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its Additional file 1.

**Declarations**

**Ethics approval and consent to participate**

The study was conducted in accordance with the Declaration of Helsinki, and its protocol was approved by the Ethics Committee of the Institute of the
Department of Second People’s Hospital of Hefei. Signed informed consents were obtained from all individuals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 24 April 2022 Accepted: 11 July 2022 Published online: 17 July 2022

References

1. Tate JR, Rifai N, Berg K, Couderc R, Dati F, Kostner GM, Sakurabayashi I, Steinmetz A. International federation of clinical chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem. 1998;44(8 Pt 1):1629–40.

2. Christiansen E, et al. Development and characterization of a potent free fatty acid receptor 1 (FFA1) fluorescent tracer. J Med Chem. 2016;59(10):4849–58.

3. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010;21(3):229–38.

4. Aggarwal DJ, Kathariya MG, Verma D. LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: looking for the ideal marker. Indian Heart J. 2021;73(5):544–8.

5. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

6. Tsai KL, et al. Baicalein protects against oxLDL-caused oxidative stress and inflammation by modulation of AMPK-alpha. Oncotarget. 2016;7(45):72458–68.

7. Hinder LM, et al. Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech. 2017;10(6):717–25.

8. Zhang Y, et al. Non-HDL-C is a better predictor for the severity of coronary atherosclerosis compared with LDL-C. Heart Lung Circ. 2016;25(10):975–81.

9. Barter P, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.

10. Weng Q, et al. Leukocyte telomere length, lipid parameters and gestational diabetes risk: a case-control study in a Chinese population. Sci Rep. 2018;9(1):8483.

11. Xu RX, et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: a Gensini score assessment. J Clin Lipidol. 2016;9(1):26–34.

12. Zhao X, et al. Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. Biomarkers. 2018;23(7):647–53.

13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Adult treatment panel III. JAMA. 2001;285(19):2486–97.

14. Packard CJ, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112(20):3058–65.

15. Kimura T, et al. Low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease–integrated-backscatter intravascular ultrasound study. Circ J. 2010;74(7):1392–8.

16. Kim JH, et al. Low density lipoprotein-cholesterol/high density lipoprotein-cholesterol ratio predicts plaque vulnerability in patients with stable angina. Korean Circ J. 2012;42(4):246–51.

17. Zhong Z, et al. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation. Lipids Health Dis. 2019;18(1):40.

18. Wang Y, et al. Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography. J Geriatr Cardiol. 2020;7(11):666–73.

19. Kunutsor SK, et al. Is high serum LDL/HDL cholesterol ratio an emerging risk factor for sudden cardiac death. Findings from the KIHD study. J Atheroscler Thromb. 2017;24(6):600–8.

20. Girard-Mauduit S. The lipid triad, or how to reduce residual cardiovascular risk? Ann Endocrinol. 2010;71(2):89–94 (Paris).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions